Ligand soars on GSK win for new Promacta use in HCV patients

20 Nov 2012

• By Donna Young

Shares of Ligand Pharmaceuticals soared as high as 17.4% on 19 November on word the US FDA gave its blessing for the company's partner, GlaxoSmithKline, to market Promacta (eltrombopag) as a treatment for thrombocytopenia, or low blood platelet counts, in patients with chronic hepatitis C virus (HCV) intended to allow them to initiate and maintain interferon-based therapy.

Shares of Ligand closed at $19.07 on 19 November, a gain of $2.40, or 14.4%.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

21 May 2025

• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

20 May 2025

• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.